BPC-157

Description

Compound Specifications

Full name	Body Protection Compound-157
Compound class	Synthetic pentadecapeptide
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Amino acid count	15
Molecular formula	C₆₂H₉₈N₁₆O₂₂
Molecular weight	1419.53 g/mol
CAS number	137525-51-0
Disulfide bridges	None — no cysteine residues present
Form	Lyophilized powder
Quantity	10mg per vial
Purity	≥99% (HPLC verified)
Storage (lyophilized)	2–8°C, protected from light
Third-party testing	Freedom Diagnostics
Manufacturing	Arizona GMP facility, USA

Research Background

BPC-157 is a stable gastric pentadecapeptide sequence derived from a partial sequence of a protective protein identified in human gastric juice. The compound supplied by Noxa Labs is synthesized, not extracted from biological material.

Its defining structural characteristic is stability in acidic conditions. Most peptides of comparable length degrade rapidly in gastric acid, which is the limiting variable in oral-administration research models. BPC-157 does not, and that property is the reason it appears in a body of literature that would be impractical to generate with a less stable sequence.

The 15-amino-acid chain contains no cysteine residues and therefore forms no disulfide bridges. This distinguishes its folding behavior, stability profile and handling requirements from cyclized peptides and from fragments of larger native proteins such as TB-500.

Published preclinical work — a substantial portion of it from research groups led by Sikiric and colleagues — has examined the compound principally in the context of angiogenic signaling, with attention to VEGFR2 expression and interaction with the nitric oxide system. These are laboratory research contexts. No conclusions regarding outcomes in humans are drawn or implied.

Handling & Storage

Lyophilized BPC-157 is stable at 2–8°C when sealed and shielded from light. For storage beyond several months, -20°C is preferred. Avoid repeated freeze-thaw cycles, which degrade peptide integrity.

Purity & Testing

Every batch is synthesized at our GMP-compliant Arizona facility and independently analyzed by Freedom Diagnostics before release. We publish HPLC purity data and endotoxin testing results — we don’t ask you to take our word for it. Certificates of Analysis are available for any lot; contact us with your order number.

View all Certificates of Analysis →

Frequently Asked Questions

What is BPC-157 derived from?
It is a synthetic 15-amino-acid sequence based on a partial sequence of Body Protection Compound, a protein identified in human gastric juice. Noxa Labs BPC-157 is synthesized, not extracted.

How is BPC-157 structurally different from TB-500?
They are unrelated molecules. BPC-157 is a complete 15-amino-acid synthetic sequence. TB-500 is a fragment corresponding to the actin-binding region of thymosin beta-4, a 43-amino-acid protein. Different origins, different structures, different proposed mechanisms.

Why does the absence of cysteine matter?
No cysteine means no disulfide bridges. The peptide does not rely on internal bonds to hold a folded conformation, which gives it a different stability and handling profile from cyclized peptides.

Does BPC-157 require refrigeration during shipping?
No. Lyophilized peptide is shelf-stable in transit and ships from Arizona. Refrigerate on arrival.

What size is available?
10mg lyophilized vials.

Related Research Compounds

• TB-500 10mg — thymosin beta-4 fragment, a structurally unrelated compound
• BPC-157 + TB-500 Blend 20mg — both compounds pre-combined in a single vial
• GLOW 70mg — three-compound blend including BPC-157
• Certificates of Analysis — batch testing data

Research Use Only

For Research Use Only. This product is intended solely for laboratory research purposes. It is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as such. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not for resale without authorization.